Skip to main content
Scheme 1. | Cancer Nanotechnology

Scheme 1.

From: Radiolabeling and PET–MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer

Scheme 1.

Preparation of nat/64Cu-MN-anti-miR10b: 1. Coupling reaction between MN-NH2 and NODAGA-NHS to form NODAGA-MN. 2. Functionalization with the hetero-bifunctional linker, SPDP. 3. Conjugation to anti-miR10b antagomir via disulfide linkage to form NODAGA-MN-anti-miR10b. 4. Complexation reaction with natCuCl2 or 64CuCl2 leading to nat/64Cu-MN-anti-miR10b

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us